Solid Biosciences CTO Sells Shares to Cover Taxes as Company Advances Gene Therapy Programs
Solid Biosciences Chief Technology Officer Paul Herzich sold 10,905 shares on February 4, 2026, to cover withholding taxes tied to vested restricted stock units. The transaction, executed at a weighted average price of $6.4419, leaves Herzich with 69,067 directly held shares. Solid Biosciences has reported clinical milestones across Duchenne and Fr…